Northrock runs a self-funded medical plan covering 2,900 lives at roughly $22.6M a year. Over four years it has added seven point solutions on top of the plan. Each one arrived with a business case. Each one has renewed at least once. Together, their vendors claim to have removed $5.02M from a $18.4M claims base — about 27 cents of every claims dollar.
Claims trend over the same period: +6.1%, then +7.8%, then +8.4%.
Both things cannot be true. That is not a scandal and nobody at Northrock has been careless — it is the ordinary arithmetic of seven vendors each measuring their own contribution against their own baseline, with nobody holding the ledger that says a dollar can only be saved once. This report is that ledger.
| Component | Annual | Share | Note |
|---|---|---|---|
| Medical & pharmacy claims | $18,400,000 | 81.5% | Paid claims, net of member cost share |
| Stop-loss premium | $1,420,000 | 6.3% | $150K specific attachment |
| Point solutions | $1,685,810 | 7.5% | Seven vendors — the subject of this report |
| ASO / administration | $1,060,000 | 4.7% | TPA, network access, PBM admin |
| Total plan cost | $22,565,810 | 100% | $15,563 per employee per year |
Concentration note: 11 members exceeded $100,000 in the trailing year, accounting for $3.9M — 21% of claims. No point solution in the portfolio is designed to reach that population. Section 06 takes this up.
Every deduction below is a specific, named correction with a method behind it. None of them assume a vendor is lying. Most of what comes out is the result of measurement designs that were never built to answer the buyer's question — they were built to answer the seller's.
The low end of that range is negative. We publish it because it is a real possibility under the assumptions stated in Section 11, and a portfolio that can plausibly return less than it costs is the single most useful thing a CFO can know before a renewal signature.
Selection bias and regression to the mean — $1.18M. Six of the seven programs measure enrolled members against their own prior-year spend. People enroll in a musculoskeletal program at the moment their back hurts most. Their spend was going to fall regardless.
Double-counted value — $864K. Four separate vendors book credit for the same avoided emergency visits, the same avoided orthopedic referrals, and the same diabetes management encounters. This one is a contracting problem, and it is fixable at renewal.
Net value is expected adjusted savings minus fully loaded annual cost. Three programs are clearly worth defending. Two are clearly worth retiring. Two sit close enough to the line that the right answer is renegotiation, not a verdict.
| Program | Cost | Vendor claim | Adjusted (low–exp–high) | Net, expected | Position |
|---|---|---|---|---|---|
| Virtual MSKVantage MSK Health | $375,300 | $1,276,020 | 95K · 210K · 385K | −$165,300 | Renegotiate or exit |
| Near-site primary careRidgeline Health | $860,000 | $2,100,000 | 870K · 1.32M · 1.71M | +$460,000 | Defend and extend |
| Behavioral health platformClearfield Behavioral | $152,250 | $620,000 | 150K · 295K · 470K | +$142,750 | Keep, absorb EAP |
| Employee assistance programCarrier-bundled | $36,540 | $95,000 | 0 · 18K · 44K | −$18,540 | Retire at renewal |
| Cardiometabolic managementMeridian Metabolic | $146,880 | $411,264 | 60K · 165K · 290K | +$18,120 | Fold in or reprice |
| Navigation & advocacyCornerstone Navigation | $82,650 | $340,000 | 0 · 62K · 155K | −$20,650 | Duplicate — retire |
| Expert second opinionSecondLook | $32,190 | $180,000 | 30K · 88K · 180K | +$55,810 | Keep — cheap tail cover |
| Portfolio | $1,685,810 | $5,022,284 | 1.21M · 2.16M · 3.23M | +$472,190 | Reallocate |
The virtual MSK program is the clearest case, so it is worth walking through in full. Nothing here requires believing the vendor did anything improper. Their measurement is internally consistent. It just answers a different question than the one Northrock is paying to have answered.
| Step | Method | Value |
|---|---|---|
| Vendor-stated return | 3.4× on fees, pre/post enrolled members | $1,276,020 |
| — of which, medical cost delta | Enrollee spend fell $1,840 PMPY × 210 members | $386,400 |
| — of which, avoided surgery credit | 14 surgeries counted as avoided, priced at plan average | $889,620 |
| Matched-cohort correction | Non-enrolled members with equivalent prior-year MSK spend fell $1,120 PMPY on their own. Incremental delta is $720, not $1,840. | $151,200 |
| Avoided-surgery re-test | Against the matched cohort's own surgical rate, 4 of 14 hold. Net of orthopedic referrals already credited to the clinic. | $58,800 |
| Axionia expected | Range $95,000 – $385,000 | $210,000 |
| Fully loaded annual cost — $9.50 PEPM on 1,450 employees ($165,300) plus per-episode fees of $1,250 on 168 completed episodes ($210,000) | $375,300 | |
| Net position | The per-episode fee is 56% of total cost and does not appear in the PEPM quote. | −$165,300 |
Enrollment is 210 of 2,900 eligible — 7.2%. Enrollees carried $4,180 in prior-year MSK spend against $890 for everyone else. A program that recruits only the acutely symptomatic will always show a large pre/post drop, because acute pain resolves. The vendor did not construct this bias; the enrollment funnel did. But the buyer pays for it either way.
At enrollment above roughly 18% of eligible members, the selection effect dilutes and the program's economics improve materially. The renegotiation worth having is not about price — it is about whether Vantage will accept a fee structure tied to reaching the other 93%.
A dollar of avoided cost can be saved once. In Northrock's portfolio, $864,000 of claimed savings is credited to more than one vendor, because each measures against a baseline that includes the others' effects. Axionia assigns each contested dollar to exactly one program using first-touch episode attribution, and shows the assignment.
| Contested amount | Value | Claimed by | Assigned to |
|---|---|---|---|
| Orthopedic referrals and physical therapy | $312,000 | Virtual MSK + Near-site clinic | Clinic — first clinical touch in 71% of episodes |
| Emergency and urgent care diversion | $247,000 | Navigation + Clinic + carrier nav line | Clinic — extended-hours access is the mechanism |
| Diabetes and hypertension management | $228,000 | Cardiometabolic + Near-site clinic | Split 60/40 — genuine co-management |
| Behavioral health first contact | $77,000 | BH platform + EAP | BH platform — EAP referred, did not treat |
| Total contested | $864,000 | 51% of annual point-solution spend | |
The pattern is not random. The clinic wins most contests because it is the first place people go. That makes it the highest-leverage asset in the portfolio — and it is also the one with the biggest access problem, which is the subject of Section 07.
Eleven members exceeded $100,000 in the trailing year and accounted for $3.9M of an $18.4M claims base. Not one of the seven point solutions in the portfolio is designed to reach them. The entire $1.69M program budget is pointed at the other 2,889 lives.
That is not automatically wrong — population health programs are built for populations. But it means the portfolio has no answer at all for the fifth of spend that moves the plan most, and it explains why claims trend can rise while every vendor reports success. The programs are working on the part of the distribution that was never going to determine the outcome.
Stop-loss premium is $1,420,000 — 6.3% of total plan cost and, at a $150,000 specific attachment, the line most exposed to this eleven. Medical stop-loss premiums rose roughly 13% nationally in 2026. For an employer of Northrock's size a single seven-figure claim is a double-digit share of annual health spend, which is why claims that were once treated as rare shock losses now have to be planned for as recurring events.
There is a second-order effect on the ledger in Section 03, and it runs in Northrock's favour rather than against it. Savings occurring above the attachment point belong to the reinsurer, not the plan. Three vendors currently count roughly $210,000 of savings that sit above it. Removing that from their claims is part of the $5.02M-to-$2.16M walk, and it is the correction vendors argue with most, because it is the one they have most often never considered.
What a portfolio designed for this would include — case-level clinical review at the point of diagnosis, centres-of-excellence steerage for transplant and oncology, a specialty-drug pathway, and stop-loss contract terms that do not laser the same eleven people next year — is outside the scope of this report. Northrock currently has none of it, and that is the largest single gap in the portfolio.
Northrock's near-site clinic is the only program in the portfolio that returns clearly more than it costs. It is open 7:00am to 4:00pm, Monday through Friday. Sixty-one percent of the production workforce is not at the plant during those hours.
Two things follow. The first is an equity finding: the most valuable health benefit Northrock offers is, in practice, available to the 30% of the workforce that already has the most schedule control. Nobody designed it that way — the clinic hours were set by the vendor's standard staffing model.
The second is an economic finding, and it points the same direction. Musculoskeletal conditions are 18.2% of Northrock's claims and are concentrated in production. The population with the highest MSK burden has the least access to the asset best positioned to manage it, and is substituting emergency care instead. Fixing the access gap and fixing the largest cost driver are the same project.
Northrock's production headcount has fallen 8% in three years while output has held, as automation absorbs routine work. The remaining production roles are increasingly skilled, harder to replace, and more expensive to lose — turnover is 26% today but the cost per departure is rising. A benefit design built for an interchangeable workforce becomes wrong quietly, and usually about two years before anyone notices.
A composite in the low 50s is unremarkable, and that is the point. Northrock is not a badly run plan. It is an ordinary one, and the verification weakness it displays is close to universal — the peer shape below is barely different. The category is under-verified, not the company.
| Dimension | Score | Peer | Reading |
|---|---|---|---|
| Value verification | 31 | 44 | No independent measurement on any of seven programs |
| Economic alignment | 38 | 52 | Six of seven contracts carry no downside for the vendor |
| Attribution discipline | 42 | 49 | $864K contested across four episode types |
| Access equity | 47 | 58 | Best asset unavailable to 61% of production |
| Workforce alignment | 51 | 55 | Design fits a workforce Northrock had in 2020 |
| Contract leverage | 55 | 51 | Three renewals inside 12 months — leverage is available |
| Plan design fit | 68 | 63 | Sound structure; specialty pharmacy is the exposure |
| Data readiness | 72 | 47 | Clean eligibility and claims feeds — better than most |
GLP-1 spend reached $1.12M last year, up from $340K two years earlier. It is the single largest source of forward uncertainty in the plan, it is not covered by any point solution in the portfolio, and it is the decision most likely to divide the CFO and the head of HR. We take a position at the end. First the numbers.
| Scenario | 3-yr expected | vs. status quo | Second-order effects |
|---|---|---|---|
| A — Maintain current coverage | $5,300,000 | — | No administrative cost. Trend risk fully retained; high case is $6.8M. |
| B — Clinical criteria, step therapy, engagement requirement | $3,300,000 | −$2,000,000 | $85K one-time administration. Affects 190–240 members. Appeals volume rises. Coverage remains available to those who meet criteria. |
| C — Sunset non-diabetes coverage, 12-month runway | $1,800,000 | −$3,500,000 | Turnover exposure of $180K–$540K against a production base already at 26%. Removes a benefit 300+ members currently use. |
Scenario B. It holds roughly 57% of the available savings while keeping the benefit in place for the members with the strongest clinical indication, and it does not ask a workforce with 26% turnover to absorb a visible takeaway in the same year. Scenario C is defensible on pure cost and we would not argue against a CFO who chose it — but the $3.5M headline overstates the real gap once retention exposure and the eventual reinstatement pressure are priced in.
We would revisit within 18 months. If the specialty pipeline behaves as the high case suggests, B becomes a bridge to C rather than a destination.
The instinct after a report like this is to cancel the losers and bank the savings. That would improve the ledger by about $119,000 and leave the two largest findings untouched. The better move uses the freed spend to fix the access gap, which is where the measurable returns are — and opens the conversation about the eleven members nothing in the portfolio currently reaches.
| Component | Low | Expected | High |
|---|---|---|---|
| Spend freed by retirement and renegotiation | $359,190 | $419,190 | $489,190 |
| Cost of shift-accessible care expansion | −$280,000 | −$245,000 | −$210,000 |
| Return on expanded access | $340,000 | $470,000 | $620,000 |
| Annual net improvement | +$419,190 | +$644,190 | +$899,190 |
| Separately, Scenario B on specialty pharmacy: −$2.0M over three years, expected case. | |||
This is not a savings guarantee and Axionia is not compensated on any of these figures. The return on expanded access is the least certain number in this report — it rests on the assumption that non-day-shift utilization rises to roughly day-shift levels within 18 months, which we have modeled but Northrock has never tested. Nothing above is credited to a high-cost-claimant strategy, because Northrock does not have one; Section 06 is a gap, not a saving.
This section exists because a recommendation you cannot audit is just a louder version of a vendor claim. If you disagree with an assumption here, the arithmetic changes and we would want to know.